Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide
- 1 June 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Coronary Artery Disease
- Vol. 14 (4), 329-334
- https://doi.org/10.1097/01.mca.0000078062.22445.60
Abstract
The accumulating evidence suggests that C-reactive protein (CRP) may have direct inflammatory effects on the vascular wall and that statin therapy may have important non-lipid anti-inflammatory effects confirmed by decreasing serum inflammatory markers, such as CRP. However, the effect of simvastatin on interleukin-6 (IL-6) release in cultured human monocytes was not investigated. DESIGN A prospective, human monocyte culture, simvastatin intervention study. Monocytes were isolated from blood of healthy volunteers by the Ficoll density gradient and stimulated by broad concentrations of CRP (1-20 microg/ml) and lipopolysaccharide (LPS, 1-10 ng/ml) at indicated time points (0, 2, 4, 8, 16 and 24 h). Also 10-8-10-6 mol/l simvastatin was coincubated with cells in the presence of CRP and LPS. Measurements of IL-6 were performed from supernatants of cultured medium in duplicate, using a commercial assay kit. CRP and LPS induced the rapid release of IL-6, with significantly elevated levels in cultured supernatants at 4 h in the CRP group and at 2 h in the LPS group. The effects of CRP and LPS on IL-6 release of monocytes were dose and time dependent. A greater than 11-fold increase of IL-6 in the CRP group (20 microg/ml) and a greater than 26-fold increase in the LPS group (10 ng/ml) were observed at 24 h compared with the control group (945.7+/-98.3 pg/ml compared with 94.3+/-12.4 pg/ml and 1720.4+/-690.1 pg/ml compared with 70.1+/-16.7 pg/ml, P<0.001, respectively). However, 10-8-10-6 mol/l simvastatin inhibited significantly the production of IL-6 in monocytes stimulated by CRP and LPS in a dose-dependent manner, with the maximal inhibiting effect at a concentration of 10-6 mol/l (945.7+/-98.3 pg/ml compared with 180.9+/-31.2 pg/ml and 1720.4+/-690.1 pg/ml compared with 824.0+/-206.2 pg/ml, P<0.001 respectively). CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin.Keywords
This publication has 23 references indexed in Scilit:
- Binding of human C-reactive protein to monocytes: analysis by flow cytometryClinical and Experimental Immunology, 2008
- Elevated Level of Plasma C-reactive Protein in Patients with Unstable Angina: Its Relations with Coronary Stenosis and Lipid ProfileAngiology, 2002
- Novel Inflammatory Markers of Coronary RiskCirculation, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart DiseaseJAMA, 1998
- Interactive Role of Infection, Inflammation and Traditional Risk Factors in Atherosclerosis and Coronary Artery Disease 11This study was supported in part by a Merit Review grant from the Department of Veterans Affairs Central Office, Washington, D.C.Journal of the American College of Cardiology, 1998
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- Inflammation, Atherosclerosis, and Ischemic Events — Exploring the Hidden Side of the MoonNew England Journal of Medicine, 1997
- C-reactive protein induces human peripheral blood monocytes to synthesize tissue factorBlood, 1993
- Elevation of C-reactive protein in “active” coronary artery diseaseThe American Journal of Cardiology, 1990